1. 2SPD-029 Stability of nivolumab solutions after transport through pneumatic tube systems. (23rd March 2022) Authors: Selmin, F; Camuffo, L; Vasile, F; Mangoni, G; Piccoli, M; Rivano, M; Cancanelli, L; Minghetti, P Journal: European journal of hospital pharmacy Issue: Volume 29(2022)Supplement 1 Page Start: A11 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 3PC-015 Short term stability of diluted solutions of the monoclonal antibody daratumumab. (24th March 2020) Authors: Mangoni, G; Selmin, F; Camuffo, L; Cancanelli, L; Piccoli, M; Rivano, M; Cervi, L; Cilurzo, F; Minghetti, P Journal: European journal of hospital pharmacy Issue: Volume 27(2020)Supplement 1 Page Start: A28 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 3PC-016 Stability of compounded nivolumab solution after pneumatic system transportation. (24th March 2020) Authors: Camuffo, L; Selmin, F; Vasile, F; Rivano, M; Piccoli, M; Mangoni, G; Cancanelli, L; Fazio, M; Cilurzo, F; Minghetti, P Journal: European journal of hospital pharmacy Issue: Volume 27(2020)Supplement 1 Page Start: A29 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 3PC-019 In use physicochemical and microbiological stability of diluted solutions of the monoclonal antibody nivolumab. (24th March 2020) Authors: Rivano, M; Selmin, F; Camuffo, L; Cancanelli, L; Mangoni, G; Piccoli, MA; Longobardo, G; Cilurzo, F; Minghetti, P Journal: European journal of hospital pharmacy Issue: Volume 27(2020)Supplement 1 Page Start: A30 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 3PC-021 Storage of nivolumab pembrolizumab and daratumumab for 14 days after compounding in the hospital pharmacy: a microbiological stability study. (24th March 2020) Authors: Cancanelli, L; Selmin, F; Camuffo, L; Mangoni, G; Piccoli, M; Rivano, M; Cilurzo, F; Minghetti, P Journal: European journal of hospital pharmacy Issue: Volume 27(2020)Supplement 1 Page Start: A31 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. 3PC-044 In use physicochemical stability of pembrolizumab under the dilution condition required for use in a day hospital. (24th March 2020) Authors: Piccoli, M; Selmin, F; Mangoni, G; Camuffo, L; Cancanelli, L; Rivano, M; Jemos, C; Cilurzo, F; Omodeo Salè, E Journal: European journal of hospital pharmacy Issue: Volume 27(2020)Supplement 1 Page Start: A42 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. 5PSQ-064 Related risk of biologic drugs for Crohn's disease in pregnancy: a case report and revision of the literature. (24th March 2020) Authors: Lucatelli, MV; Roperti, M; Bacci, C; Camuffo, L; Puzziferri, R; Pieri, G Journal: European journal of hospital pharmacy Issue: Volume 27(2020)Supplement 1 Page Start: A179 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. 5PSQ-072 Acute promyelocytic leukaemia after infliximab therapy in a crohn's disease patient: a case report and a review of the literature. (March 2019) Authors: Camuffo, L; Lucatelli, MV; Pieri, G; Bacci, C; Inzalaco, G; Puzziferri, R; Di Carlo, C; Fazio, M Journal: European journal of hospital pharmacy Issue: Volume 26(2019)Supplement 1 Page Start: A234 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗